Bringing the Trial to the Patient

Advances in communication, information, and monitoring technologies have enabled the advent of decentralized clinical trials, but the COVID-19 pandemic crystalized the interest of regulators and trial sponsors. In fact, most biopharmaceutical companies today now expect to use elements of decentralized clinical trials in studies going forward. Science 37 is providing a software platform to enable decentralized clinical trials and offering a range of services on top of that to meet the needs of trails sponsors. We spoke to Jonathan Cotliar, chief medical officer of Science 37, about the move toward decentralized clinical trials, how technology is changing the types of data that can be gathered, and how it is forever reshaping clinical trials.